JDQ443 + trametinib + Ribociclib + cetuximab
Phase 1/2ActiveDevelopment Stage
KRAS G12C Mutant Solid Tumors
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal
Oct 24, 2022 → Nov 30, 2026
About JDQ443 + trametinib + Ribociclib + cetuximab
JDQ443 + trametinib + Ribociclib + cetuximab is a phase 1/2 stage product being developed by Novartis for KRAS G12C Mutant Solid Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT05358249. Target conditions include KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05358249 | Phase 1/2 | Active |
Competing Products
20 competing products in KRAS G12C Mutant Solid Tumors